ArticleInfectious diseases of poverty2017
Apropos: critical analysis of molluscicide application in schistosomiasis control programs in Brazil.
Article in Infectious diseases of poverty, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Article
- Chemical Control of Snail Vectors as an Integrated Part of a Strategy for the Elimination of Schistosomiasis-A Review of the State of Knowledge and Future Needs.Tropical medicine and infectious disease · 2024Review
- Transmission potential of human schistosomes can be driven by resource competition among snail intermediate hosts.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Molluscicidal and parasiticidal activities of Eryngium triquetrum essential oil on Schistosoma mansoni and its intermediate snail host Biomphalaria glabrata, a double impact.Parasites & vectors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is a snail-transmitted infectious disease affecting over 200 million people worldwide. Snail control has been recognized as an effective approach to interrupt the transmission of schistosomiasis, since the geographic distribution of this neglected tropical disease is determined by the presence of the intermediate host snails. In a recent Scoping Review published in Infectious Diseases of Poverty, Coelho and Caldeira performed a critical review of using molluscicides in the national schistosomiasis control programs in Brazil. They also described some chemical and plant-derived molluscicides used in China. In addition to the molluscicides described by Coelho and Caldeira, a large number of chemicals, plant extracts and microorganisms have been screened and tested for molluscicidal actions against Oncomelania hupensis, the intermediate host of Schistosoma japonicum in China. Here, we presented the currently commercial molluscicides available in China, including 26% suspension concentrate of metaldehyde and niclosamide (MNSC), 25% suspension concentrate of niclosamide ethanolamine salt (SCNE), 50% niclosamide ethanolamine salt wettable powder (WPN), 4% niclosamide ethanolamine salt dustable powder (NESP), 5% niclosamide ethanolamine salt granule (NESG) and the plant-derived molluscicide "Luowei". These molluscicides have been proved to be active against O. hupensis in both laboratory and endemic fields, playing an important role in the national schistosomiasis control program of China. Currently, China is transferring its successful experiences on schistosomiasis control to African countries. The introduction of Chinese commercial molluscicides to Africa, with adaptation to local conditions, may facilitate the progress towards the elimination of schisosomiasis in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.